Acumen Pharmaceuticals (NASDAQ: ABOS) stepped into the spotlight at the Alzheimer’s Association International Conference (AAIC) 2026 in London this week, where the clinical-stage biopharma unveiled…
Viridian Therapeutics (NASDAQ: VRDN) shares gained 40% Tuesday after the company unveiled positive topline results from the Phase 3 REVEAL-2 clinical trial of elegrobart in…